Daewon Pharmaceutical Statistics

Total Valuation

Daewon Pharmaceutical has a market cap or net worth of KRW 315.93 billion. The enterprise value is 455.89 billion.

Market Cap	315.93B
Enterprise Value	455.89B

Important Dates

The next estimated earnings date is Wednesday, November 13, 2024.

Earnings Date	Nov 13, 2024
Ex-Dividend Date	n/a

Share Statistics

Daewon Pharmaceutical has 21.43 million shares outstanding. The number of shares has decreased by -0.16% in one year.

Shares Outstanding	21.43M
Shares Change (YoY)	-0.16%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	38.80%
Owned by Institutions (%)	13.04%
Float	12.98M

Valuation Ratios

The trailing PE ratio is 21.75 and the forward PE ratio is 8.50.

PE Ratio	21.75
Forward PE	8.50
PS Ratio	0.55
PB Ratio	1.17
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.11, with an EV/FCF ratio of -27.93.

EV / Earnings	31.04
EV / Sales	0.81
EV / EBITDA	10.11
EV / EBIT	17.02
EV / FCF	-27.93

Financial Position

The company has a current ratio of 1.19, with a Debt / Equity ratio of 0.68.

Current Ratio	1.19
Quick Ratio	0.63
Debt / Equity	0.68
Debt / EBITDA	4.27
Debt / FCF	-11.72
Interest Coverage	3.71

Financial Efficiency

Return on equity (ROE) is 4.70% and return on invested capital (ROIC) is 3.92%.

Return on Equity (ROE)	4.70%
Return on Assets (ROA)	3.18%
Return on Capital (ROIC)	3.92%
Revenue Per Employee	449.28M
Profits Per Employee	11.66M
Employee Count	1,260
Asset Turnover	1.09
Inventory Turnover	2.77

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -8.08% in the last 52 weeks. The beta is 0.42, so Daewon Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	0.42
52-Week Price Change	-8.08%
50-Day Moving Average	15,215.00
200-Day Moving Average	15,030.60
Relative Strength Index (RSI)	48.75
Average Volume (20 Days)	139,903

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Daewon Pharmaceutical had revenue of KRW 566.09 billion and earned 14.69 billion in profits. Earnings per share was 677.80.

Revenue	566.09B
Gross Profit	273.15B
Operating Income	26.47B
Pretax Income	16.68B
Net Income	14.69B
EBITDA	44.76B
EBIT	26.47B
Earnings Per Share (EPS)	677.80

Full Income Statement

Balance Sheet

The company has 63.46 billion in cash and 191.31 billion in debt, giving a net cash position of -127.85 billion or -5,964.91 per share.

Cash & Cash Equivalents	63.46B
Total Debt	191.31B
Net Cash	-127.85B
Net Cash Per Share	-5,964.91
Equity (Book Value)	279.98B
Book Value Per Share	12,637.73
Working Capital	41.23B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.23 billion and capital expenditures -19.55 billion, giving a free cash flow of -16.32 billion.

Operating Cash Flow	3.23B
Capital Expenditures	-19.55B
Free Cash Flow	-16.32B
FCF Per Share	-761.42

Full Cash Flow Statement

Margins

Gross margin is 48.25%, with operating and profit margins of 4.68% and 2.59%.

Gross Margin	48.25%
Operating Margin	4.68%
Pretax Margin	2.95%
Profit Margin	2.59%
EBITDA Margin	7.91%
EBIT Margin	4.68%
FCF Margin	-2.88%

Dividends & Yields

This stock pays an annual dividend of 300.00, which amounts to a dividend yield of 2.04%.

Dividend Per Share	300.00
Dividend Yield	2.04%
Dividend Growth (YoY)	-14.29%
Years of Dividend Growth	n/a
Payout Ratio	43.29%
Buyback Yield	0.16%
Shareholder Yield	2.21%
Earnings Yield	4.60%
FCF Yield	-5.17%

Dividend Details

Stock Splits

The last stock split was on March 7, 2022. It was a forward split with a ratio of 1.03.

Last Split Date	Mar 7, 2022
Split Type	Forward
Split Ratio	1.03

Scores

Daewon Pharmaceutical has an Altman Z-Score of 2.47. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.47
Piotroski F-Score	n/a